Review: taking Elavil and Elmiron together


Summary

Drug interactions are reported among people who take Elavil and Elmiron together. This review analyzes the effectiveness and drug interactions between Elavil and Elmiron. It is created by eHealthMe based on reports of 248 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Elavil and Elmiron >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Elavil

Elavil has active ingredients of amitriptyline hydrochloride. It is often used in depression. (latest outcomes from Elavil 12,717 users)

Elmiron

Elmiron has active ingredients of pentosan polysulfate sodium. It is often used in cystitis interstitial. (latest outcomes from Elmiron 2,167 users)

On Aug, 25, 2016

248 people who take Elavil, Elmiron are studied.


Number of reports submitted per year:

Elavil and Elmiron drug interactions.

Drug effectiveness over time:

Elavil:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 50.0% - (1 of 2 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 50.0% - (1 of 2 people)
  • not specified: 0.0% - (0 of 0 people)
Elmiron:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 33.0% - (1 of 3 people)
  • 10+ years: 0.0% - (0 of 1 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Elavil:
  • female: 33.0% - (3 of 9 people)
  • male: 0.0% - (0 of 0 people)
Elmiron:
  • female: 22.0% - (2 of 9 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Elavil:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 2 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 33.0% - (1 of 3 people)
  • 60+: 100.0% - (1 of 1 people)
Elmiron:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 50.0% - (1 of 2 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 0.0% - (0 of 3 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • chest pain
  • nausea
  • nervousness
  • hypomenorrhoea
  • metrorrhagia
  • therapeutic response unexpected
  • vaginal haemorrhage
1 - 6 months:
  • cholecystitis chronic
  • depression
  • gallbladder disorder
  • inflammation
  • mental disorder
  • pain
  • weight gain - unintentional
  • breast cancer
  • confusional state
  • hepatic enzyme increased
6 - 12 months:
  • loose stools
1 - 2 years:
  • migraine - common
  • platelet count increased
  • vertigo
  • colitis ulcerative
  • faecal incontinence
2 - 5 years:
  • bone loss
  • muscle twitching
5 - 10 years:
  • vertigo
  • elevated liver enzymes
  • migraine - common
  • platelet count increased
10+ years:
  • elevated liver enzymes
  • abdominal pain upper
  • dry mouth
  • dysuria
  • micturition urgency
  • neuralgia
  • somnolence
  • urinary retention
not specified:
  • pain
  • pain in extremity
  • arthralgia
  • anxiety
  • dizziness
  • hypoaesthesia
  • fall
  • neuralgia
  • osteoarthritis
  • femur fracture

Most common drug interactions by gender *:

female:
  • pain
  • pain in extremity
  • arthralgia
  • anxiety
  • dizziness
  • hypoaesthesia
  • neuralgia
  • fall
  • osteoarthritis
  • femur fracture
male:
  • halo vision
  • alopecia
  • amyotrophic lateral sclerosis
  • blood ph increased
  • chest pain
  • colonoscopy
  • cough
  • cystitis interstitial
  • drug ineffective
  • dyspnoea

Most common drug interactions by age *:

10-19:
  • bleeding time prolonged
  • erythema
  • nausea
  • petechiae
  • rash maculo-papular
20-29:
  • cholecystitis chronic
  • depression
  • gallbladder disorder
  • inflammation
  • melaena
  • mental disorder
  • pain
  • rectal bleeding
  • activities of daily living impaired
  • aggression
30-39:
  • asthenia
  • dyspnoea
  • nausea
  • oedema peripheral
  • pain
  • pain in extremity
  • chest pain
  • deep vein thrombosis
  • fatigue
  • hypoaesthesia
40-49:
  • depression
  • urinary tract infection
  • weight increased
  • application site vesicles
  • arthralgia
  • drug ineffective
  • fall
  • joint injury
  • oropharyngeal pain
  • pain
50-59:
  • pain
  • arthralgia
  • insomnia
  • pyrexia
  • mouth ulceration
  • pain in extremity
  • dry mouth
  • accidental overdose
  • anxiety
  • bone disorder
60+:
  • dyspnoea
  • pain in extremity
  • back pain
  • drug ineffective
  • headache
  • anxiety
  • dyspepsia
  • femur fracture
  • neuralgia
  • thyroid neoplasm

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Elavil and Elmiron?

Can you answer these questions?

More questions for: Elavil, Elmiron

You may be interested in these reviews

More reviews for: Elavil, Elmiron

On eHealthMe, Elavil (amitriptyline hydrochloride) is often used to treat depression. Elmiron (pentosan polysulfate sodium) is often used to treat cystitis interstitial. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.